Understanding PTEN regulation: PIP2, polarity and protein stability
- PMID: 18794881
- DOI: 10.1038/onc.2008.243
Understanding PTEN regulation: PIP2, polarity and protein stability
Abstract
The PTEN tumour suppressor is a lipid and protein phosphatase that inhibits phosphoinositide 3-kinase (PI3K)-dependent signalling by dephosphorylating phosphatidylinositol 3,4,5-trisphosphate (PtdInsP(3)). Here, we discuss the concept of PTEN as an 'interfacial enzyme', which exists in a high activity state when bound transiently at membrane surfaces containing its substrate and other acidic lipids, such as PtdIns(4,5)P(2) and phosphatidylserine (PtdSer). This mechanism ensures that PTEN functions in a spatially restricted manner, and may explain its involvement in forming the gradients of PtdInsP(3), which are necessary for generating and/or sustaining cell polarity during motility, in developing neurons and in epithelial tissues. Coordinating PTEN activity with alternative mechanisms of PtdInsP(3) metabolism, by the tightly regulated SHIP 5-phoshatases, synthesizing the independent second messenger PtdIns(3,4)P(2), may also be important for cellular polarization in some cell types. Superimposed on this interfacial mechanism are additional post-translational regulatory processes, which generally act to reduce PTEN activity. Oxidation of the active site cysteine residue by reactive oxygen species and phosphorylation of serine/threonine residues at sites in the C-terminus of the protein inhibit PTEN. These phosphorylation sites also appear to play a role in regulating both stability and localization of PTEN, as does ubiquitination of PTEN. Because genetic studies in mice show that the level of expression of PTEN in an organism profoundly influences tumour susceptibility, factors that regulate PTEN, localization, activity and turnover should be important in understanding its biological functions as a tumour suppressor.
Similar articles
-
Ubiquitination of PTEN (phosphatase and tensin homolog) inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress.J Biol Chem. 2010 Apr 23;285(17):12620-8. doi: 10.1074/jbc.M109.072280. Epub 2010 Feb 22. J Biol Chem. 2010. PMID: 20177066 Free PMC article.
-
Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors.J Immunol. 2002 Nov 15;169(10):5441-50. doi: 10.4049/jimmunol.169.10.5441. J Immunol. 2002. PMID: 12421919
-
5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells.Mol Cell Biol. 2000 Sep;20(18):6860-71. doi: 10.1128/MCB.20.18.6860-6871.2000. Mol Cell Biol. 2000. PMID: 10958682 Free PMC article.
-
The regulation of cell migration by PTEN.Biochem Soc Trans. 2005 Dec;33(Pt 6):1507-8. doi: 10.1042/BST0331507. Biochem Soc Trans. 2005. PMID: 16246156 Review.
-
Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN.Biochem Soc Trans. 2001 Nov;29(Pt 6):846-51. doi: 10.1042/0300-5127:0290846. Biochem Soc Trans. 2001. PMID: 11709086 Review.
Cited by
-
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.Cancer Res. 2010 Jul 1;70(13):5305-15. doi: 10.1158/0008-5472.CAN-09-3399. Epub 2010 Jun 8. Cancer Res. 2010. PMID: 20530665 Free PMC article.
-
Eukaryotic chemotaxis: a network of signaling pathways controls motility, directional sensing, and polarity.Annu Rev Biophys. 2010;39:265-89. doi: 10.1146/annurev.biophys.093008.131228. Annu Rev Biophys. 2010. PMID: 20192768 Free PMC article. Review.
-
A new class of cancer-associated PTEN mutations defined by membrane translocation defects.Oncogene. 2015 Jul;34(28):3737-43. doi: 10.1038/onc.2014.293. Epub 2014 Sep 29. Oncogene. 2015. PMID: 25263454 Free PMC article.
-
Smurf1 regulates lung cancer cell growth and migration through interaction with and ubiquitination of PIPKIγ.Oncogene. 2017 Oct 12;36(41):5668-5680. doi: 10.1038/onc.2017.166. Epub 2017 Jun 5. Oncogene. 2017. PMID: 28581524
-
Gastric cancer and the epoch of immunotherapy approaches.World J Gastroenterol. 2015 May 21;21(19):5778-93. doi: 10.3748/wjg.v21.i19.5778. World J Gastroenterol. 2015. PMID: 26019442 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials